Replies to post #1485 on NanoViricides Inc. (NNVC)

[BonelessCat]

I agree with your take on this. The GSK PR was unfiltered by the press, and met uncritically by the market analysts. The thing is, the statement that the drug is a major setback for everyone else is a total overreach. The drug is still preclinical, the same as most others, and by their own admission still has a long way to go before market.